Last deal

$20M

Amount

Debt Financing

Stage

10.08.2021

Date

2

all rounds

$56M

Total amount

date founded

Financing round

General

About Company
Visus Therapeutics is developing innovative ophthalmic therapies to improve vision worldwide.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2019

Number of employees

Last funding type

Debt Financing

IPO status

Private

Description

Visus Therapeutics is a clinical-stage pharmaceutical company developing innovative ophthalmic therapies, including a once-daily eye drop for presbyopia. They are also working on other ophthalmic product candidates for various eye conditions. Additionally, they have partnered with DelSiTech Ltd to develop advanced drug delivery technology. Their goal is to improve vision for people worldwide.
Contacts

Social url

Similar Companies
1000
ONL Therapeutics

ONL Therapeutics

ONL Therapeutics develops therapeutics for retinal diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Therapeutics

Location

Ann Arbor, MI, USA

total rounds

9

total raised

$82.94M
LENZ Therapeutics

LENZ Therapeutics

LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Pharmaceuticals

Location

Coronado, CA, USA

total rounds

5

total raised

$217.4M
OcuCure Therapeutics

OcuCure Therapeutics

OcuCure Therapeutics is developing topical eye drops for the treatment of age-related macular degeneration and diabetic retinopathy.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Medical

Location

Roanoke, VA, USA

total rounds

7

total raised

$3.25M
Kuria Therapeutics

Kuria Therapeutics

Kuria Therapeutics is a pharmaceutical company developing a novel topical Nrf2 activator for eye and skin diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Little Rock, AR, USA

total rounds

1

Financials

Funding Rounds
2
2

Number of Funding Rounds

$56M

Money Raised

Their latest funding was raised on 10.08.2021. Their latest investor Johnson & Johnson Innovation – JJDC. Their latest round Debt Financing

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Life Sciences Partners

Life Sciences Partners

LSP is a leading European investment firm that finances private and public life-science companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Financial Services, Finance

Location

Amsterdam, Netherlands

count Of Investments

142

count Of Exists

29
RTW Investments LLC

RTW Investments LLC

RTW Investments is an innovative health care investment firm.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Financial Services, Health Care

Location

New York, NY, USA

count Of Investments

90

count Of Exists

3
Co-Investors
Investors
5
2

Number of lead investors

5

Number of investors

Investor 
Lead 
Round 
Partners 
No
Debt Financing, Series A
No
Series A
Johnson & Johnson Innovation – JJDC

Johnson & Johnson Innovation – JJDC

JJDC helps innovative healthcare ideas become real solutions for patients.

Sector

Health Care Providers

Subsector

Health Care Services

Keywords

Health Care

Location

Cambridge, MA, USA

count Of Investments

79

count Of Exists

3
RTW Investments LLC

RTW Investments LLC

RTW Investments is an innovative health care investment firm.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Financial Services, Health Care

Location

New York, NY, USA

count Of Investments

90

count Of Exists

3
Tony Nguyen

Tony Nguyen

Tony Nguyen is a managing director at RTW Investments. He serves as an Analyst at RTW, where he leads the commercial analysis of biopharma and medical technology assets. He is also the founding member of the firm’s internal Valuation Committee. Tony’s focus on the commercial viability of new drugs and technologies is a critical component of RTW’s work. We are living in an age where diseases are being redefined based on their genetic causes, and it is of paramount importance to understand the changing opportunity set of addressable patients across diseases. Tony received a BS in Electrical Engineering from the National University of Singapore and an MBA from St. John’s University, both on a full academic scholarship. POST NAVIGATION

Wille AG

Wille AG

Location

Zürich, Switzerland

count Of Investments

7

count Of Exists

1

People

Founders
1
Benjamin Bergo
Benjamin Bergo

Benjamin Bergo

Ben Bergo is the Co-Founder, Executive Director, Chief Executive Officer & Board Member at Visus Therapeutics.

current job

Visus Therapeutics
Visus Therapeutics

organization founded

1

Benjamin Bergo

Employee Profiles
3
Jehan Tamboowalla

Jehan Tamboowalla

SVP, Head of Business Development and Marketing

Ben Bergo

Ben Bergo

Chief Executive Officer

Benjamin Bergo

Benjamin Bergo

Co-Founder, Executive Director, Chief Executive Officer & Board Member

Activity

Recent News
6
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month